Published in AIDS Weekly, September 12th, 2005
"Racivir [RCV; (±)-beta-2',3'-dideoxy-5-fluoro-3'-thiacytidine], a 50:50 racemic mixture of the two P nucleoside enantiomers, is currently in development for the treatment of human immunodeficiency virus type I (HIV-1) infections.
"RCV was administered once a day orally for 14 days at doses of 200, 400, or 600 mg in combination with stavudine and efavirenz to HIV-1-infected treatment-naive male volunteers in a phase Ib/IIa study," scientists writing in the journal Antimicrobial Agents and Chemotherapy report.
"Six volunteers at each dose were...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.